Lugano-based InVirtuoLabs has raised €2.85M in funding to revolutionize drug discovery. The startup aims to cut drug development costs and time through advanced machine learning and AI. Plans include team expansion, collaborations, and platform capabilities enhancement over the next 18 months. Their innovative platform can generate billions of new drug candidates, significantly increasing success rates and targeting critical areas like rare diseases. This will combat high costs and lengthy timelines in current drug development practices, directly impacting treatments for diseases linked to important nuclear receptors.
"The integration of artificial intelligence, chemistry, and molecular biophysics is radically changing the way we develop drugs," says Gianvito Grasso, Founder and CEO of InVirtuoLabs.
"Our system is not limited to analysing existing data, but generates and tests billions of new molecules, identifying the best ones for efficacy and safety, particularly for rare diseases," adds Grasso.
Collection
[
|
...
]